Oppenheimer Downgrades Optimer Pharmaceuticals (OPTR) to Perform
More News related to OPTR
- After-Hours Movers 2/4: PWER, OPTR, PTIX, HA, TSYS Higher; PWAV, TTMI, MFLX, SNCR, BMI Lower
- Optimer Pharmaceuticals (OPTR) Announces Positive Phase 3 Results
- Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Clostridium Difficile Infection
- Ladenburg Thalmann Upgrades Optimer Pharmaceuticals (OPTR) to Buy
- Notable Insider Trades 12/29 (LM, OPTR, MED, CTXS, AM, COST, more...)
More News related to Downgrades
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
- Davenport Downgrades Electronic Arts (ERTS) to Sell; Lowers Q4, 2010-11 Estimates
- Stifel Nicolaus Downgrades Parkway Properties (PKY) to Sell
- Craig-Hallum Downgrades Terremark (TMRK) to Accumulate
Oppenheimer downgrades Optimer Pharmaceuticals (Nasdaq: OPTR) from Outperform to Perform.
To see more analyst ratings on OPTR Click Here.
Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide.
Related Categories
DowngradesStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
